Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evocation Trial of evolocumab before PCI
jRCTs051180022Completed
- Sponsor
- Amgen
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of evolocumab in coronary arteriosclerosis and hypercholesterolemia (2 arms), sponsored by Amgen. Primary endpoint: Index of microvascular resistance after PCI. Started Mar 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on jRCTs051180022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180022.